Abstract
A new series of N, \(N^{\prime }\)-bis-oxazolidinones-sulfone and 5-chloromethylsulfamoyl-oxazolidin-2-ones have been synthesized in three steps (carbamoylation, sulfamoylation and cyclization) starting from 1,3-dichloroporopan-2-ol, chlorosulfonyl isocyanate and primary or secondary amines. Synthesis has been carried out following simple methodology in excellent isolated yields. The structure and purity of the original compounds were confirmed by IR, NMR, and MS. The compounds were evaluated for their in vitro antibacterial activity against some Gram-positive bacteria; Staphylococcus aureus and Gram-negative bacteria; Escherichia Coli, Klebsiella pneumonieae, Acinetobacter, Pseudomonas aeruginosa, Enterococcus, Salmonella sp. The compounds showed moderate to good antibacterial activity.
Similar content being viewed by others
References
(a) Raether W and Hanel H 2003 Parasitol. Res. 219; (b) Fluit A C, Schmitz F J, Verhoef J and Milatovic D 2002 J. Antimicrob. Chemother. 50 271; (c) Robert L, Goldenberg M D, John C, Hauth M D and William W A 2000 N. Engl. J. Med. 342 1500; (d) Kavita d, Yumna A, Meenakshi A, Swapnil S and Jaya D 2013 J. Chem. Sci. 125 1093
Brichner S J, Hutchinson D K, Barbachyn M R, Manninen P R, Ulanowicz D A, Garmono S A, Grega K C, Hendges S K, Toops D S, Ford C W and Zurenko G E 1996 J. Med. Chem. 39 673
Patel R, Rouse M S, Piper K E and Steckelberg J M 1999 Diagn. Microbiol. Infect. Dis. 34 119
Gonzales R D, Schreckenberger P C, Graham M B, Kelkar S, DenBesten K and Quinn J P 2001 Lancet 357 1197
Tsiodras S, Golod H S, Sakoulas G, Eliopoulos G M, Wennersten C, Venkataraman L, Moellering R C and Ferraro M J 2001 Lancet 358 207
Xiong L, Kloss P, Douthwaite S, Anderson N M, Swaney S, Shinabarge D C and Mankin A S 2000 J. Bacteriol. 182 5325
Mutnick A H, Enne V and Jones R N 2003 Ann. Phermacother. 37 769
Brunton L, Lazo J S and Parker K L 2006 In The Pharmacological Basis of Therapeutics 11th edn. (New York: Goodman & Gilman’s)
Scozzafava A, Owa T, Mastrolorenzo A and Supuran C T 2003 Curr. Med. Chem. 10 925
Supuran C T, Scozzafava A and Casini A 2003 Med. Res. Rev. 23 146
Casini A, Scozzafava A, Mastrolorenzo A and Supuran C T 2002 Curr. Cancer. Drug. Targets 2 55
Owa T and Nagasu T 2000 Exp. Opin. Ther. Pat. 10 1725
Supuran C T and Scozzafava A 2002 Exp. Opin. Ther. Pat. 12 217
Supuran C T and Scozzafava A 2001 Curr. Med. Chem. Imm. Endoc. Metab. Agents 1 61
Supuran C T and Scozzafava A 2000 Exp. Opin. Ther. Pat. 10 575
Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi N H, Nagasu T, Koyanagi N and Kitoh K 1999 J. Med. Chem. 42 3789
Funahashi Y, Sugi N H, Semba T, Yamamoto Y, Hamaoka S, Tsukahara-Tamai N, Ozawa Y, Tsuruoka A, Nara K, Takahashi K, Okabe T, Kamata J, Owa T, Ueda N, Haneda T, Yonaga M, Yoshimatsu K and Wakabayashi T 2002 Cancer Res. 62 6116
Abbate F, Casini A, Owa T, Scozzafava A and Supuran C T 2004 Bioorg. Med. Chem. Lett. 14 217
Brown G M 1971 Adv. Enzymol. Relat. Areas Mol. Biol. 35 35
Ford C W, Zurenko G E and Barbachyn M R 2001 Curr. Drug Targ.-Infect. Dis. 1 181
Wayne P A 1997 National Committee for Clinical Laboratory Standards Approved Standard. M7-A4 M27
(a) Jorgensen J H, Turnidge J D, Washington J A 1999 In Manual of Clinical Microbiology 7th ed. Murray P R, Pfaller M A, Tenover F C, Baron E J and Yolken R H (eds.) (Washington, DC: ASM Press) pp. 1526-1543; (b) National committee for Clinical Laboratory Standards. Performance Standards for antimicrobial susceptibility testing; ninth informational supplement. 1999 M100-S9 Vol 19 No. 1 (Wayne, Pennsylvania: NCCLS) Table 21
Kartal M, Yýldýz S, Kaya S, Kurucu S and Topc U G 2003 J. Ethnopharmacol. 86 69
Berredjem M, Bouchareb F, Ait Kaki S, Dekhil M and Aouf N E 2013 Arab. J. Chem. doi: 10.1016/j.arabjc.2013.01.016
Bouchareb F, Boufas W, Cheloufi H, Berredjem M and Aouf N E 2014 Phosphorus Sulfur Silicon Relat. Elem. 189 587
(a) Barbey C, Bouasla R, Berredjem M, Dupont N, Retailleau P, Aouf N E and Lecouvey M 2012 Tetrahedron 68 9125; (b) Berredjem M, Bouasla R, Aouf N and Barbey C 2010 X-ray Structure Analysis on Line 26 13
Berredjem M, Regainia Z, Dewynter G, Montero J L and Aouf N E 2006 Heteroat. Chem. 17 1
Bouasla R, Berredjem H, Berredjem M, Ibrahim-Oualid M, Allaoui A, Lecouvey M and Aouf N E 2013 J. Het. Chem. 50 1328
Cheloufi H, Berredjem M, Boufas W, Bouchareb F, Djahoudi A and Aouf N E 2014 Phosphorus, Sulfur Silicon Relat. Elem. 189 1396
(a) Bouchouk D, Colacino E, Toupet L, Aouf N E, Martinez J and Dewynter G 2009 Tetrahedron Lett. 50 1100; (b) Berredjem M, Djebbar H, Regaïnia Z, Aouf N E, Dewynter G, Winum J Y and Montero J L 2003 Phosphorus, Sulfur Silicon Relat. Elem. 178 693
Acknowledgments
This work was generously supported by the Direction Générale de la Recherche Scientifique et du Développement Technologique, DGRS-DT, Algerian Ministry of Scientific Research (FNR 2000).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information
All additional information pertaining to characterization of the N-sulfamoyloxazolidin-2-ones using ESI-MS technique (figures S14, S15), 1H NMR spectrum (figures S8, S10, S12, S13), 13C NMR spectrum (figures S9, S11), are given in the supporting information which available at www.ias.ac.in/chemsci.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
BOUCHAREB, F., BERREDJEM, M., KAKI, S.A. et al. Synthesis and antibacterial activity of new chiral N-sulfamoyloxazolidin-2-ones. J Chem Sci 128, 85–91 (2016). https://doi.org/10.1007/s12039-015-1004-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12039-015-1004-x